Related Experiment Videos
MIR-27a regulates the TGF-β signaling pathway by targeting SMAD2 and SMAD4 in lung cancer
Dong-Kyu Chae1,2, Eunmi Ban1, Young Sook Yoo1
1Molecular Recognition Research Center, Korea Institute of Science and Technology, Seongbuk-gu, Seoul, South Korea.
Abstract:
The transforming growth factor-β (TGF-β) signaling pathway is associated with carcinogenesis and various biological processes. SMAD2 and SMAD4, which are putative tumor suppressors, have an important role in TGF-β signaling. The aberrant expression of these genes is implicated in some cancers. However, the mechanisms of SMAD2 and SMAD4 dysregulation are poorly understood. In this study, we observed that miR-27a was upregulated in lung cancer cell lines and patients. In addition, SMAD2 and SMAD4 genes were identified as targets of miR-27a by several target prediction databases and experimental validation. Functional studies revealed that miR-27a overexpression decreased SMAD2 and SMAD4 mRNA and protein levels. Furthermore, miR-27a contributed to cell proliferation and invasion by inhibiting TGF-β-induced cell cycle arrest. These results suggest that miR-27a may function as an oncogene by regulating SMAD2 and SMAD4 in lung cancer. Thus, miR-27a may be a potential target for cancer therapy.
Insights
MicroRNA-27a (miR-27a) acts as an oncogene in lung cancer by upregulating SMAD2 and SMAD4. This dysregulation inhibits TGF-β signaling, promoting cancer cell proliferation and invasion, suggesting miR-27a as a therapeutic target.
Area of Science:
- Molecular Biology
- Oncology
- Gene Regulation
Background:
- Transforming growth factor-β (TGF-β) signaling is crucial in biological processes and carcinogenesis.
- SMAD2 and SMAD4 are tumor suppressors vital for TGF-β signaling, with their aberrant expression linked to cancer.
- Mechanisms underlying SMAD2 and SMAD4 dysregulation in cancer remain unclear.
Purpose of the Study:
- Investigate the role of miR-27a in lung cancer.
- Determine if miR-27a targets SMAD2 and SMAD4.
- Elucidate the functional impact of miR-27a on TGF-β signaling and lung cancer progression.
Main Methods:
- Bioinformatic target prediction for miR-27a.
- Experimental validation of miR-27a targets (SMAD2, SMAD4).
- Analysis of miR-27a expression in lung cancer cell lines and patient samples.
- Functional assays assessing cell proliferation, invasion, and cell cycle arrest.
Main Results:
- miR-27a was found to be upregulated in lung cancer.
- SMAD2 and SMAD4 were validated as direct targets of miR-27a.
- miR-27a overexpression reduced SMAD2 and SMAD4 mRNA and protein levels.
- miR-27a inhibited TGF-β-induced cell cycle arrest, promoting proliferation and invasion.
Conclusions:
- miR-27a functions as an oncogene in lung cancer by targeting SMAD2 and SMAD4.
- Dysregulation of the miR-27a/SMAD2/SMAD4 axis contributes to lung cancer development.
- miR-27a represents a potential therapeutic target for lung cancer treatment.